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Abstract
The aim of the chapter is to raise awareness about recent constructs of negative symptoms,
their burden on patients, caregivers and society, and about their management. Schizo-
phrenia consists of positive, negative, and cognitive symptoms. However, treating physi-
cians are not necessarily aware about recent constructs of negative symptoms, their
presence at prodromal stage, and the distinction among primary, secondary, persistent,
prominent, or predominant negative symptoms. Negative symptoms have a substantial
impact on the day-to-day functioning of patients with schizophrenia and contribute more
to impaired quality of life and poor functioning than positive symptoms do. Additionally,
they are associated with high costs for society and a substantial burden for caregivers.
Negative symptoms are not adequately treated by available antipsychotic therapies. Pub-
lications have shown that no antipsychotic has a beneficial effect when compared to
another. Cariprazine is the only antipsychotic that has proven superiority over another
antipsychotic (risperidone) in one clinical study.
Keywords: primary, secondary, prominent, predominant, negative symptoms, deficit
syndrome, alogia, affect blunted, avolition, anhedonia, asociality, antipsychotic treatment
1. Introduction
It is well known and established in the scientific community that schizophrenia symptoms can
be categorized as positive, negative, and cognitive. While positive symptoms are easy to
recognize, negative symptoms are often more difficult to distinguish, as they can be mistaken
for depressive symptoms [1, 2]. For the treatment of schizophrenia symptoms, several antipsy-
chotics were discovered, developed, and registered from the 1950s. These drugs are efficiently
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improving the positive symptoms of schizophrenia but have slight or no effect on the negative
and cognitive symptoms. Since no real treatment was available for negative symptoms, little
focus has been laid on this particular field of the disease so far. With very recent development
approaches and the new potential treatments on the horizon, discussions on how to define,
distinguish, and treat negative symptoms are increasing day by day.
Negative symptoms are a key element of schizophrenia including symptoms such as blunt
affect, lack of motivation, asociality, and impoverished speech. They are associated with
disruptions and/or lack of normal emotions and behavior [1, 3]. These symptoms may occur
with or without positive symptoms and can, at times, be difficult to recognize as part of the
disorder.
Recently, a consensus has been reached on how to describe negative symptoms [4]:
Five constructs (the 5 “A”) were identified as negative symptoms namely affect (blunted),
alogia, anhedonia, asociality, and avolition and were clustered into two factors: one including
blunted affect and alogia and the other consisting of anhedonia, avolition, and asociality
(Table 1). For each construct, symptoms due to identifiable factors, such as medication effects,
Blunted affect and alogia cluster
Affect blunted/flat affect
Blunted affect refers to a decrease in emotions and expressions. Patients may appear immobile, lifeless,
and have a wooden expression [5]. They may make little to no eye contact and speak in a dull monotone
voice [1]. Absence of emotions is called flat affect [3]
Alogia
Patients with schizophrenia often have reduced speech and may give short answers to questions. Many
questions may be required in order to receive sufficiently detailed information from the patient [3, 6]
Anhedonia, avolition and asociality cluster
Avolition
Avolition refers to lack of motivation, sense of purpose, or ability to follow through on plans. For
example, the patient may have a desire or interest to grow a garden but never act on the plan [6]
Anhedonia
Anhedonia refers to lack of pleasure. Patients suffering from schizophrenia may not take interest in
activities they previously enjoyed. For example, a patient who was an avid gardener before may have
a complete lack of interest in gardening when suffering from schizophrenia [5]
Asociality/Social withdrawal
Patients with schizophrenia may exhibit social withdrawal, show diminished interest and pleasure in
social interactions, and often neglect activities of daily living (such as personal hygiene) [1, 3]. Asociality
should not be defined in purely behavioral terms (whether the subject has social interactions and close
relationships), but mainly as a reduction in motivation for social contacts (whether the subject values and
desires social interactions and close social bonds) [7, 8]
Table 1. Characteristics of the most important negative symptoms.
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psychotic symptoms or depression, should be distinguished from those regarded as core symp-
toms of the disease.
Besides this new adaptation, negative symptoms can also be characterized as primary, second-
ary, prominent, predominant or persistent, as deficit syndrome, or clustered as Liemburg “core
negative symptoms” and “expressive deficit” clusters. Table 2 gives an overview of frequently
used negative symptom definitions.
2. Differential diagnosis
Negative symptoms can be part of various conditions/diseases and must be distinguished
from those related to schizophrenia. The most important differentiation for clinical practice is
between primary and secondary negative symptoms. While primary negative symptoms are
considered a core symptom of schizophrenia, which persist during clinical stability [9], sec-
ondary negative symptoms are believed to be a consequence of other factors such as:
Primary Considered a core symptom of schizophrenia which persist during clinical stability [9]
Secondary A consequence of positive symptoms, neurological side effects, depressive symptoms, or
environmental factors [10, 11]
Deficit syndrome Presence of at least two out of the following six negative symptoms in patients meeting
criteria for schizophrenia: 1. restricted affect (referring to observed behavior), 2. diminished
emotional range (i.e., reduced range of the patient’s subjective emotional experience), 3.
poverty of speech, 4. curbing of interests, 5. diminished sense of purpose, 6. diminished
social drive for at least 12 months including periods of clinical stability. The above symptoms
are primary, i.e., not secondary to factors such as anxiety, drug effect, psychotic symptoms,
intellectual disability or depression [12–14]
Prominent Prominent negative symptoms were defined as: 1. Baseline score ≥4 on at least 3, or ≥5 on at
least 2 negative PANSS subscale items; or 2. PANSS negative score >3 on item 1 and item 6
and at least one third item with a score >3 and a maximum of two items with a score >3 from
the positive subscale [15, 16]
Predominant Predominant negative symptoms were defined as: 1. Baseline score ≥4 on at least 3 or ≥5 on
at least 2 of the 7 negative subscale items and a PANSS positive score of <19; 2. PANSS
negative score ≥6 points over PANSS positive score; 3. PANSS negative score of at least 21
and at least 1 point greater than the PANSS positive score and 4. A common sense
definition, negative subscale greater than positive subscale [15, 16]
Persistent Persistent negative symptoms are defined as the presence of at least one negative symptom
of moderate or higher severity, not confounded by depression or parkinsonism, at baseline
and after 1 year of treatment [17]
Liemburg—core negative
symptoms
Avolition, anhedonia
(Intensity of expected pleasure from activities diminished, asocial behavior) [18]
Liemburg—expressive
deficit
Blunted affect, alogia
(Facial expression, expressive gestures, vocal expression, spontaneous elaboration, quantity
of speech diminished) [18]
Table 2. List and characteristics of frequently used negative symptom definitions.
Negative Symptoms of Schizophrenia: Constructs, Burden, and Management
http://dx.doi.org/10.5772/intechopen.73300
45
• positive symptoms (for example, social withdrawal because of paranoid ideas),
• neurological side effects of antipsychotic treatment (Parkinson like symptoms),
• depressive symptoms
• or environmental factors (social under stimulation due to hospitalization) [10, 11].
The importance of distinguishing primary from secondary negative symptoms lies in its
therapeutic implication; while secondary negative symptoms can be improved by removing
the underlying cause, primary negative symptoms are likely to persist despite treatment [9].
Additionally, negative symptoms, especially symptoms of anhedonia, avolition, and asociality
can also occur in a number of other psychiatric diseases including depressive episodes, sub-
stance abuse, and internal or neurological disorders [19]. Schizoaffective disorder, depressive
type (ICD-10 F25.1), and severe major depressive disorder with psychotic symptoms (ICD-10
F32.3) are two diseases that are particularly difficult to distinguish from schizophrenia with
negative symptoms. Schizoaffective disorder, depressive type is “a disorder in which both
schizophrenic and depressive symptoms are prominent, so that the episode of illness does not
justify a diagnosis of either schizophrenia or depressive episode” [20]. The patient experiences
a combination of schizophrenia symptoms, such as hallucinations or delusions, and mood
symptoms, such as potentially anhedonia, avolition, and asociality. Severe major depressive
disorder with psychotic symptoms is a disease where “the patient suffers from lowering of
mood, reduction of energy, and decrease in activity. Capacity for enjoyment, interest, and
concentration is reduced, and marked tiredness after even minimum effort is common. The
lowered mood varies little from day to day, is unresponsive to circumstances, and may be
accompanied by so-called ‘somatic’ symptoms, such as loss of interest and pleasurable feel-
ings, marked psychomotor retardation, agitation, loss of appetite, weight loss, and loss of
libido. Hallucinations, delusions, psychomotor retardation, or stupor so severe that ordinary
social activities are impossible” might be present [20]. A correct diagnosis and distinction from
schizophrenia with negative symptoms has a great impact on therapy in these diseases: while
for schizoaffective disorder and major depressive disorder the therapy includes antidepres-
sants next to antipsychotics [21], for negative symptoms of schizophrenia, this has not been
shown as effective [22].
The differential diagnosis of blunted affect includes next to schizophrenia, post-traumatic
stress disorder (PTSD). PTSD is a mental disorder that is triggered by a terrifying event (war,
torture, sexual assault). Symptoms include flashbacks, nightmares, inability to feel positive
emotions, dissociative symptoms, severe anxiety, and avoidance of triggers [19]. Blunted affect,
anhedonia, and feelings of detachment are also core symptoms of PTSD, which cause dimin-
ished interest in activities that produce pleasure, and reduced tendency of emotional expres-
sions [23].
Alogia is caused by a dysfunction in the fronto-striatal area of the brain and can therefore also
occur in several neurological diseases (such as Huntington’s and Parkinson’s diseases, demen-
tia, etc.) [24]. However, physical symptoms that accompany such diseases make the differenti-
ation from schizophrenia not so difficult.
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Overall, it can be concluded that while symptoms of anhedonia, avolition, and asociality also
occur in the course of several other diseases (especially those with depressive episodes), blunted
affect and alogia seem to be more inherent to schizophrenia with negative symptoms [25].
3. Course
Schizophrenia typically begins with a prodromal period, which precedes first episode psychosis
and can last from a few days to around 18 months. The prodromal period and the very early
phases of the disease are characterized by negative symptoms [26]. In contrast, early stages and
acute exacerbations are more characterized by positive symptoms. Over time, the positive
symptoms diminish due to treatment or due to the natural course of the illness and are replaced
by more prominent negative symptoms. Finally, during the residual phase of the illness, nega-
tive symptoms are most prevalent [27]. Figure 1 shows a typical course of the disease.
Although this is a common pattern for schizophrenia, the course can vary considerably. Some
patients have psychotic episodes lasting weeks or months with full remission of their symp-
toms between each episode; others have a fluctuating course in which symptoms are continu-
ous but rise and fall in intensity; yet others have relatively little variation in the symptoms of
their illness over time.
In order to define clinically relevant course variants, a healthcare professional needs to be able
to characterize both the current state as well as the longitudinal pattern of the illness in the
individual patient [28]. For this, ICD-10 provides the following course specifiers [20] (Table 3).
At one end of the spectrum, the person has a single psychotic episode of schizophrenia
followed by complete recovery; at the other end of the spectrum is a course in which the illness
never abates and debilitating effects increase (Figure 2).
Negative symptoms are common in the prodromal phase of the disease, in between psychotic
episodes and at the end of the disease in the residual phases. According to the ICD-10, which
Figure 1. Individual clinical course of schizophrenia (adapted from American Psychiatric Association [32]).
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classifies schizophrenia into different subtypes (Table 4), negative symptoms prominently
occur in hebephrenic, simple, and residual schizophrenia.
Hebephrenic schizophrenia is “a form of schizophrenia in which affective changes are prominent,
delusions and hallucinations fleeting and fragmentary, behavior irresponsible and unpredictable,
Class Course
F20.x0 Continuous; no remission of psychotic symptoms throughout the period of observation
F20.x1 Episodic; with a progressive development of “negative” symptoms in the intervals between psychotic
episodes
F20.x2 Episodic; with persistent but nonprogressive “negative” symptoms in the intervals between psychotic
episodes
F20.x3 Episodic (remittent); with complete or virtually complete remissions between psychotic episodes
F20.x4 Incomplete remission
F20.x5 Complete or virtually complete remission
F20.x8 Other pattern of course
F20.x9 Course uncertain, period of observation too short
Table 3. ICD-10 course specifiers.
Figure 2. Overall clinical course of schizophrenia (adapted from Schizophrenia.com).
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and mannerisms common. The mood is shallow and inappropriate, thought is disorganized,
and speech is incoherent. There is a tendency to social isolation. Usually, the prognosis is poor
because of the rapid development of ‘negative’ symptoms, particularly flattening of affect and
loss of volition. Hebephrenia should normally be diagnosed only in adolescents or young
adults” [20].
“Simple schizophrenia is a disorder in which there is an insidious but progressive development
of oddities of conduct, inability to meet the demands of society, and decline in total perfor-
mance. The characteristic negative features of residual schizophrenia (e.g., blunting of affect
and loss of volition) develop without being preceded by any overt psychotic symptoms” [20].
“Residual schizophrenia is a chronic stage in the development of a schizophrenic illness in
which there has been a clear progression from an early stage to a later stage characterized by
long-term, though not necessarily irreversible, ‘negative’ symptoms, e.g., psychomotor slow-
ing; underactivity; blunting of affect; passivity and lack of initiative; poverty of quantity or
content of speech; poor nonverbal communication by facial expression, eye contact, voice
modulation and posture; poor self-care and social performance” [20].
In summary, negative symptoms constitute a core element of the disease. They dominate the
clinical picture at the beginning and at the end of the disease but are also found in between
psychotic episodes.
4. Epidemiology
Historically, applying different diagnostic criteria for patients with negative symptoms has
affected the incidence and prevalence numbers of such patients. Depending on the diagnostic
criteria applied, negative symptoms may comprise 5–60% of patients with schizophrenia, as
shown by Rabinowitz et al., who found that in a large sample of negative symptom patients,
8.1–62.3% met criteria for prominent negative symptoms and 10.2–50.2% met criteria for
F20.0 Paranoid schizophrenia
F20.1 Hebephrenic schizophrenia
F20.2 Catatonic schizophrenia
F20.3 Undifferentiated schizophrenia
F20.4 Post-schizophrenic depression
F20.5 Residual schizophrenia
F20.6 Simple schizophrenia
F20.8 Other schizophrenia
F20.9 Schizophrenia, unspecified
Table 4. Subtypes of schizophrenia according to ICD-10.
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predominant negative symptoms [16]. Bobes reported that approximately 60% of individuals
with schizophrenia-spectrum disorders experience one or more negative symptoms [29] and
about 13% of the schizophrenic patients could be described as having primary negative
symptoms [29]. Buchanan claimed 15–20% experience enduring negative symptoms that are
primary to the disorder [27]. In a further study by Sicras-Mainar, it was reported that 52% of
the patients presented one or more negative symptoms, the most common being passive/
apathetic social withdrawal and emotional withdrawal [30, 31]. Furthermore, the prevalence
of negative (deficit) states has been estimated to be 15% in first episode patients, 25–30% in
clinical samples and 14–17% in population studies [9].
In conclusion, it is evident that negative symptoms are highly prevalent in the schizophrenic
population.
5. Risk factors
Brain imaging, electrophysiological, and oculomotor data, showing either less or different
abnormalities in negative symptom patients (here defined as deficit syndrome), suggest that
deficit syndrome represents a separate disease entity with respect to other forms of schizo-
phrenia, and not just the extreme end of a severity continuum. This is further supported by
evidence that deficit syndrome has different risk factors than general schizophrenia [9].
These are
• male gender—while in general schizophrenia, there is no difference in gender [9, 32]
• summer births, compared to a winter birth in general schizophrenia [9]
• serum antibodies to cytomegalovirus [9]
• low serum folate concentration [9]
• higher genetic contribution in negative symptoms than to positive symptoms [27]
• obstetric complications [33]
• structural abnormalities, such as enlarged ventricles [33]
• dysfunctional beliefs about performance (increased defeatist performance beliefs), accep-
tance, likelihood of success, and resources, which reduce motivation [33]
6. Burden
Negative symptoms account for much of the long-term morbidity, poor functional outcomes,
and high rates of disability in patients with schizophrenia [14, 34, 35]. They have a substantial
impact on the day-to-day functioning of patients affecting the ability to live independently, to
perform activities of daily living, to be socially active, to maintain personal relationships, and
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to work and study [16, 36–40]. Research evidence suggests that the negative symptoms of
schizophrenia contribute more to impaired quality of life and poor functioning than positive
symptoms do [35, 38, 41] and that their severity is associated with a lower quality of life [42].
The three major challenges of schizophrenia’s negative symptoms are their modest therapeutic
response, pervasiveness, and diminution of patients’ quality of life and functioning [43].
Evidence suggests that even after significant improvements in psychotic symptoms, patients
with schizophrenia continue to experience poor quality of life due to residual negative symp-
toms, depression/anxiety, or cognitive impairment [44].
Mohr et al. (using their own definition of disease states based on the PANSS, as described
above) found that patients who began therapy in disease state four (high negative symptoms
but low to moderate other symptoms) seemed relatively intractable to treatment, with lower
odds ratios than patients starting in disease states five (cognitive impairment predominant)
and seven (positive predominant) [45].
Negative symptoms are major contributors to low function levels and deterioration in most
patients with schizophrenia, because poorly motivated patients cannot function at school or
work, cannot maintain relationships with family and friends in the face of unresponsive affect,
and do not develop personal interests when experiencing anhedonia, apathy, and inattention [43].
One longitudinal study showed that negative symptoms predicted long-term impairment in
global psychosocial functioning and work performance, with negative symptom severity being
a significant individual predictor of the degree of impairment in relationships [34]. Addition-
ally, the degree of impairment in participation and enjoyment of recreational activities was
significantly correlated with the severity of negative symptoms [34].
Negative symptoms affect patients’ ability to cope with daily activities and have a negative
impact on their quality of life. Negative symptoms are relatively common and account for
much of the long-term morbidity and poor functional outcome of patients with schizophrenia.
Patients with schizophrenia have severe problems with personal and social relations, which
affect their quality of life (QoL) [46]. Negative symptoms, in particular, are often enduring and
lead to poor functional outcomes in individuals with schizophrenia [47]. Increased risk of
suicide, an unhealthy lifestyle, poor physical health, and CV disease (which is a leading cause
of death) are main reasons associated with excess early mortality in schizophrenia [31].
Negative symptoms are recognized by both the Food and Drug Administration (FDA) and
European Medicines Association (EMA) as features of schizophrenia that are not adequately
treated by available antipsychotic therapies and are considered a valid target for drug devel-
opment [16]. Negative symptoms can often persist despite psychosocial treatments and anti-
psychotic medication [47, 48].
As previously discussed, increased costs are positively correlated with lower functioning and
negative symptoms are the major contributor to low function levels in patients with schizo-
phrenia. Patients with negative symptoms have been shown to use more healthcare resources
(including primary care, emergency care, and specialized care visits, laboratory tests, radiology
Negative Symptoms of Schizophrenia: Constructs, Burden, and Management
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tests, and pharmaceutical prescriptions), especially with regard to primary care visits [30]. The
highest direct costs are due to a high frequency of hospital admissions in negative symptom
patients [49]. In addition to this direct cost, negative symptoms represent a burden for patients,
caregivers, and society and therefore constitute a relevant economic burden [30].
7. Treatment
With the development of second-generation antipsychotics, there was initially hope within the
medical community of targeting the negative and cognitive symptoms, as well as the positive
symptoms of schizophrenia. Indeed, various therapeutic guidelines suggest second-generation
antipsychotics (SGAs) over first-generation antipsychotics (FGAs); however, this suggestion is
controversial.
The second-generation antipsychotics demonstrated efficacy in treating positive symptoms
with less motor side effects than first-generation antipsychotics (with accompanied improve-
ment in secondary negative symptoms), but the treatment goal of also improving the primary,
negative, and cognitive symptoms was not achieved with these medications [22].
To explore any differential efficacy against negative symptoms, Leucht et al. [50] conducted a
meta-analysis of 150 RCTs that directly compared an FGA with an SGA and included data
from more than 21,000 patients. They found that four SGAs (clozapine, olanzapine,
amisulpride, and risperidone) were most effective overall, but also specifically with respect to
negative symptoms, when compared to FGAs. The magnitude of this difference, however, was
small, with the largest effect size reported being 0.32 for olanzapine. With respect to EPS side
effects, these four drugs were better than high dose FGAs but not when compared to low
doses. The findings of pragmatic studies comparing the clinical effectiveness of SGAs and
FGAs in schizophrenia [51, 52] are consistent with the findings of Leucht et al. meta-analysis.
More recent publications have shown that no drug has a beneficial effect on negative symp-
toms when compared to another [53–55]. In the only meta-analysis assessing available treat-
ments for negative symptoms versus placebo, some statistically significant differences were
found for various treatments (e.g., second-generation antipsychotics, antidepressants,
glutamatergic agents, psychological interventions), but no effect reached the level of clinically
significant improvement [55].
The results of the Cutlass1 study showed no advantage of second-generation drugs in terms of
quality of life or symptoms over 1 year in patients with schizophrenia. In fact, those partici-
pants receiving a first-generation antipsychotic did rather better. In addition, there were no
significant differences in rates of objectively assessed extrapyramidal side effects [51].
Amisulpride, the most widely studied antipsychotic in patients with negative symptoms, is
indicated for negative symptoms in several European countries. However, most of the evi-
dence showing efficacy is versus placebo and was obtained from clinical trials that were
conducted in the 1990s (before the introduction of the current EMA recommendations)
[56–59]. When amisulpride was evaluated in two recent studies conducted in patient populations
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specifically selected for predominant negative symptoms, the findings for amisulpride were
equivocal [60]. A 6-month trial comparing olanzapine (5 or 20 mg/d) and amisulpride 150 mg/
d with placebo only found significant improvement for low-dose olanzapine versus placebo,
but not for amisulpride [61]. Additionally, in a 12-week double-blind trial comparing amisul-
pride and ziprasidone, equivalent improvement in negative symptoms was demonstrated for
both drugs [62]. Improvement in patient functioning in conjunction with negative symptom
improvement was not investigated in any of these studies [54], and pseudospecificity param-
eters were also not well controlled for.
Scant information is currently available to guide clinicians on the treatment of negative symp-
toms. This leads to
• Treatment guidelines rarely mentioning treatment of negative symptoms specifically, and
if they do, they suggest second-generation antipsychotics. Table 5 gives a few examples of
treatment guideline suggestions. It is agreed that these antipsychotics are to be used for
the treatment of negative symptoms, because so far no effective therapies were available.
The scientific community agrees, however, that current antipsychotics do not adequately
address negative symptoms. Therefore, it is to be shown, how therapeutic guidelines will
change once an agent is available that shows better efficacy on negative symptoms than
other antipsychotics.
• Physicians prescribing various medications including anxiolytics, antidepressants, and
anticonvulsants, which sometimes add little value and create unnecessary polypharmacy
[22]. Antidepressants are a common treatment choice given the overlap between predomi-
nant negative symptoms and depressive symptoms, but supporting evidence is limited [63].
In the light of these facts, it is paramount to find efficacious therapies for negative symptoms,
as there is a huge unmet medical need. Extensive research is ongoing, and there are some
promising agents in development that could potentially be used for negative symptom treat-
ment later on [60, 64, 65]. However, at the moment, only one antipsychotic exists, which has
shown superiority over another antipsychotic in the treatment of negative symptoms in a well-
designed study examining treatment effects on primary, persistent negative symptoms and
that agent is cariprazine [60].
Cariprazine is a new D3/D2 partial agonist antipsychotic with preferential binding to D3
receptors. Cariprazine differs from all available antipsychotics due to its higher affinity for D3
receptors, which is higher than that of any other antipsychotic or in fact than dopamine itself.
Cariprazine can therefore affect a D3 receptor blockade [66] that no other antipsychotic can.
Since the blockade of D3 receptors has been shown to be related to improvement of negative
and cognitive symptoms [67], it is assumed that cariprazine’s blockade of D3 receptors is
responsible for its effects on negative symptoms.
This was demonstrated in a randomized, double-blind, risperidone-referenced clinical trial
[60]. The study enrolled schizophrenic patients with persistent (at least 6 month), predominant
(high level on negative symptoms low level of positive symptom), primary (extrapyramidal
symptoms (EPS), high positive symptoms and depression were exclusionary) negative symp-
toms. After the 26 week treatment period, cariprazine-treated patients showed significant
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improvement in negative symptoms (measured by PANSS-Factor Score for Negative Symp-
toms /PANSS-FSNS/) and patient functionality (Personal and Social Performance /PSP/) alike
compared to risperidone. Subanalyses of individual negative symptom items and PSP
subdomains measuring day-to-day functioning showed that this effect was global and not
only driven by selected items [60].
Responder analyses have a primary position in defining the clinical relevance of study results.
In this study, these analyses with a 20 and 30% cut-off were both in favor of cariprazine over
risperidone. One of the strongest methods to evaluate clinical relevance of PANSS results is the
combined rate of CGI (improved/very much improved) with responder rates at 30 and 20%
reduction level. Also here, cariprazine showed a clear, significant superiority of over risperidone.
Organization Terminology Recommendation
World Federation of
Societies of Biological
Psychiatry (2012)
Negative symptoms “For primary negative symptoms, treatment with
certain SGAs (amisulpride, aripiprazole, clozapine,
olanzapine, quetiapine, ziprasidone), but not with
FGAs, is recommended with inconsistent evidence
and with the need for more studies to prove the
efficacy.”
British Association for
Psychopharmacology
(2011)
Recommendations for the
pharmacological management of
negative symptoms
“Psychotic illness should be identified and treated
as early as possible as this may offer some protection
against the development of negative symptoms.
For any given patient, the antipsychotic that gives the
best balance between overall efficacy and side effects
should be used.”
British Association for
Psychopharmacology
(2011)
Where negative symptoms persist
beyond an acute episode of
psychosis
“To ensure EPS (specifically bradykinesia) and
depression are detected and treated if present, and
consider the contribution of the environment to
negative symptoms (e.g., institutionalization, lack
of stimulation).
Consider augmentation of antipsychotic treatment
with an antidepressant such as an SSRI, ensuring that
choice is based on minimizing the potential for
compounding side effects through pharmacokinetic
or pharmacodynamic drug interactions.
If clozapine is prescribed, consider augmenting with
lamotrigine or a suitable second antipsychotic.”
American Psychiatric
Association (2010)
Negative symptoms “Treatment of negative symptoms begins with
assessing the patient for syndromes that can cause the
appearance of secondary negative symptoms. The
treatment of such secondary negative symptoms
consists of treating their causes, e.g., antipsychotics
for primary positive symptoms, antidepressants for
depression, anxiolytics for anxiety disorders, or
antiparkinsonian agents or antipsychotic dose
reduction for extrapyramidal side effects. If negative
symptoms persist, they are presumed to be primary
negative symptoms of the deficit state. There are no
treatments with proven efficacy for primary negative
symptoms.”
Table 5. Treatment guideline suggestions for negative symptoms treatment.
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The results are clinically relevant, especially bearing in mind that a significant difference over a
comparator is much more difficult to achieve than over placebo, since the active comparator
would be assumed to also have some activity [60].
Differences in PANSS total score, positive subscale score, general psychopathology, depression
scale, or EPS scales were minimal and not statistically significant, substantiating that the change
seen on negative symptoms was not due to improvement in secondary negative symptoms [60]
but a true improvement on primary negative symptoms.
With no standard of care available for negative symptoms, the choice of risperidone in this
study might be subject to potential criticism; however, it is the right choice considering the
alternatives. Since the late 1990s, second-generation antipsychotics are the preferred treatment
over first-generation antipsychotics. From the existing and available second-generation anti-
psychotics, only four are known to have somewhat better efficacy on negative symptoms, and
these are clozapine, olanzapine, amisulpride, and risperidone [50]. Of these four:
• Clozapine is not considered a valid first-line treatment due to its severe side-effect profile.
It is only a valid therapy if other antipsychotics have failed.
• Olanzapine is an effective antipsychotic medication and has, however, a completely dif-
ferent adverse event profile than cariprazine: its high weight gain and sedative properties
would have unblinded the study. Therefore, it could not be used for this study. However,
olanzapine was studied in a similarly designed negative symptom study and compared to
asenapine. Olanzapine was not better in controlling negative symptoms of schizophrenia
than asenapine [68], and its change from baseline to week 26 on the PANSS FSNS was
lower (7.1) than change from baseline to week 26 with cariprazine (8.9).
• Amisulpride would have been a potential choice, since it is approved for the treatment of
negative symptoms of schizophrenia in some European countries. However, which dose
to choose is a challenging question: amisulpride is used in different doses for the treat-
ment of positive symptoms (400–800 mg) and for the treatment of negative symptoms
(50–300 mg) with no overlapping between the two dose ranges. Since the aim of the study
was equally to improve negative symptoms and to keep positive symptoms well under
control, no dose could be chosen as a well-established and empirically proven dose.
Differences in equivalent doses and side-effect profiles further blurred the picture.
• Finally, risperidone was chosen, because it has a similar side-effect profile and a similar
dose range to cariprazine. As no antipsychotic is considered truly better than another in
the treatment of negative symptoms, risperidone is considered a valid choice and served
as a representative for all antipsychotics. Risperidone kept the positive and depressive
symptoms, as well as the level of EPS, well under control.
Other comparators for the study could have been placebo or aripiprazole. However,
• no empiric evidence is available for aripiprazole being an effective therapy for negative
symptoms,
• and placebo would have been controversial from an ethical perspective (leaving patients
untreated for 26 weeks). Moreover, such a study would have measured relapse rates instead
of efficacy on negative symptoms and the results would have been difficult to interpret.
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Additionally, cariprazine has demonstrated efficacy in the treatment of acute schizophrenic
symptoms [44, 69, 70] as well as in relapse prevention and maintenance treatment [71]. It is
generally safe and well tolerated and has a manageable safety profile. In a recent meta-analysis
by Leucht et al. [72], several drugs were examined after 60 years of available antipsychotic
treatment. Efficacy data on primary negative symptoms were not examined, but data on safety
in the short-term acute schizophrenia trials were presented. Cariprazine showed a favorable
safety profile concerning weight gain, QT prolongation, and prolactin increase [72] compared
to the other antipsychotics.
8. Conclusions
Negative symptoms such as blunted affect, alogia, anhedonia, avolition, and asociality can be
clustered into two main clusters: blunted affect and alogia cluster and anhedonia, avolition,
and asociality cluster [4]. They can be further characterized as primary (key element of schizo-
phrenia, and inherent to the disease) and secondary (due to external factors such as side
effects, depression or positive symptoms). They affect patients’ ability to cope with daily
activities and have a negative impact on their quality of life.
Negative symptoms are relatively common (15–60%), and account for much of the long-term
morbidity and poor functional outcome of patients with schizophrenia [16, 29–31, 68]. Despite
the introduction of second-generation antipsychotics in the 1990s, the clinical management of
these symptoms continued to be an unmet medical need [30]. Though these agents are very
effective in managing positive symptoms of schizophrenia, they have relatively poor long-
term efficacy for negative symptoms. Thus, many patients are left with negative symptoms
after their positive symptoms have been partially or completely controlled [29].
Cariprazine is a new D3/D2 partial agonist antipsychotic with preferential binding, and sub-
sequent blockade of D3 receptors [66]. Since the blockade of D3 receptors is assumed to be
related to an improvement in negative and cognitive symptoms [67], cariprazine is assumed to
be effective in the treatment of negative symptoms. This has been demonstrated in a well-
designed clinical trial where cariprazine has shown a statistically significant improvement in
negative symptoms and patient functioning compared to risperidone. Cariprazine has also
shown to have an acceptable safety profile, with advantages in weight gain, QT prolongation
and hyperprolactinemia compared to other antipsychotics [72].
In summary, with no antipsychotic therapies available for the treatment of primary negative
symptoms, cariprazine is an exciting new potential. It could be the first-in-class compound and
a game changer in the treatment of negative symptoms. With demonstrated efficacy on posi-
tive [44, 69–71] and negative symptoms [60], and a manageable safety profile, cariprazine
monotherapy covers the full range of schizophrenic symptoms and could be a good long-
term treatment choice for schizophrenia.
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